Key Market Indicator:
Ad-hoc news is mandatory information from listed companies that must be made available to investors. Depending on the occasion and content of the news, it can have an impact on the share price. The newsfeed covers a wide range of topics relevant to investor relations and is recommended as an important source of information before making an investment decision.
Fri, 03.05.2024
Wolford AG
May 3, 2024
Regis Rimbert has been appointed by the Supervisory Board of Wolford AG as a member of the Executive Board for one year with effect from May 6, 2023. As Chief Transformation Officer, he will support and drive forward the further transformation of the company.
End of Inside Information
03-May-2024 CET/CEST News transmitted by EQS Group [ … ]
Fri, 03.05.2024
Amundi Physical Metals plc
Amundi Physical Metals plc
(« Issuer »)
Release of the Base Prospectus (the “Prospectus”)
AMUNDI PHYSICAL GOLD ETC (the “ETC”)
Series of debt securities governed by Irish Law
Dublin, May 3, 2024
The Issuer announces that it has made available to the public the Prospectus of the ETC dated on 3 may 2024.
The Base Prospectus is avai [ … ]
Fri, 03.05.2024
Amundi Physical Metals plc
Amundi Physical Metals plc
(« Issuer »)
Release of the Base Prospectus (the “Prospectus”)
AMUNDI PHYSICAL GOLD ETC (the “ETC”)
Series of debt securities governed by Irish Law
Dublin, May 3, 2024
The Issuer announces that it has made available to the public the Prospectus of the ETC dated on 3 may 2024.
The Base Prospectus is avai [ … ]
Thu, 02.05.2024
Leifheit Aktiengesellschaft
Leifheit Aktiengesellschaft: Management Board of Leifheit AG resolved share buy-back program with a total volume of up to € 8.5 million with the approval of the Supervisory Board
Nassau/Germany, 2 May 2024 – Considering the robust liquidity situation, the Board of Management of Leifheit AG (ISIN DE0006464506) resolved with the approval of the Supe [ … ]
Thu, 02.05.2024
Deutsche Konsum REIT-AG
Deutsche Konsum REIT-AG in continued negotiations on the extension of the corporate bonds maturing in the short term
Potsdam, 2 May 2024 - The negotiations conducted by Deutsche Konsum REIT-AG ("DKR") (ISIN DE000A14KRD3) with the bondholders regarding extensions of the maturity of (i) the EUR 70 million unsecured bond maturing on 3 May 2024 (ISIN D [ … ]
Thu, 02.05.2024
European Healthcare Acquisition & Growth Company B.V.
Public disclosure of inside information according to Article 17 para. 1 of the Regulation (EU) No 596/2014 on market abuse (Market Abuse Regulation)
European Healthcare Acquisition & Growth Company B.V. announces change in CEO position
Munich, May 2, 2024
European Healthcare Acquisitions & Growth Company B.V. (“EHC”) received the resi [ … ]
Thu, 02.05.2024
AEVIS VICTORIA SA
Ad hoc announcement pursuant to Art. 53 LR
Fribourg, 2 May 2024
AEVIS VICTORIA SA (AEVS.SW) – Revenues from operating divisions are increasing, with positive forecasts for the current year. Growth for 1Q2024 is 7.2%.
AEVIS VICTORIA SA (AEVIS) reported consolidated revenues for the first quarter of 2024 of CHF 281.9 million (1Q2023: CHF 263.0 mi [ … ]
Wed, 01.05.2024
Vitruvia Medical AG
Vitruvia Medical AG: Year End results as of December 31, 2023
Anglikon, May 1st , 2024: Vitruvia Medical AG achieved a result after taxes of CHF -243,864.40 in the past year 2023 compared to CHF -1,095,349.38 in the previous year.
On a consolidated basis, Vitruvia Medical AG generated revenue of EUR 1,7575,724.00 (previous year: EUR 1,525,529.00) [ … ]
Wed, 01.05.2024
Vitruvia Medical AG
Vitruvia Medical AG: Year End results as of December 31, 2023
Anglikon, May 1st , 2024: Vitruvia Medical AG achieved a result after taxes of CHF -243,864.40 in the past year 2023 compared to CHF -1,095,349.38 in the previous year.
On a consolidated basis, Vitruvia Medical AG generated revenue of EUR 1,7575,724.00 (previous year: EUR 1,525,529.00) [ … ]
Tue, 30.04.2024
Spexis AG
Ad hoc announcement pursuant to Art. 53 LR
Allschwil, Switzerland, April 30, 2024
Spexis receives approval of an extension of the deadline for the publication of its 2023 annual report and audited financials until latest May 31, 2024.
Spexis AG (SIX: SPEX), a clinical-stage biopharmaceutical company focused on macrocycle therapeutics for ra [ … ]